SEC Filings

Form 8-K
BEIGENE, LTD. filed this Form 8-K on 08/01/2018
Document Outline
Entire Document (785.6 KB)
Subdocument 1 - 8-K - 8-K
Page 1 - UNITED STATES
Page 2 - Item 1.01 Entry into a Material Definitive Agreement.
Page 3 - Item 9.01 Financial Statements and Exhibits.
Page 4 - Exhibit Index
Page 5 - SIGNATURES
Subdocument 2 - EX-1.1 - EX-1.1
Page 1 - Exhibit 1.1
Page 2 - N/A
Page 3 - THIS AGREEMENT is made on 27 July 2018
Page 4 - NOW IT IS HEREBY AGREED as follows:
Page 5 - Accepted Hong Kong Public Offering Applications means the Hong Kong Public Offering Applications whi
Page 6 - Companies (Winding Up and Miscellaneous Provisions) Ordinance means the Companies (Winding Up and Mi
Page 7 - Hong Kong Offer Shares means 5,904,000 new Shares being initially offered by the Company under the H
Page 8 - International Offer Shares means 59,696,000 Shares initially proposed to be offered by the Company f
Page 9 - Listing Committee means the listing committee of the SEHK;
Page 10 - PHIP means the post hearing information pack of the Company posted on the SEHK s website at www.hkex
Page 11 - Taxation or Taxes means all forms of taxation whenever created, imposed or arising and whether of Ho
Page 12 - Headings: The headings in this Agreement are for convenience only and shall not affect the interpret
Page 13 - in agreed form shall mean in the form of the draft thereof agreed in writing between the Company and
Page 14 - Procure fulfilment: The Company undertakes to the Hong Kong Underwriters to use its best endeavours
Page 15 - Determination of Offer Price: The Company and the Joint Global Coordinators (on behalf of the Hong K
Page 16 - Joint sponsors: The Company hereby confirms and acknowledges its appointment, to the exclusion of al
Page 17 - No liability for Offer Price and Offering Documents: Notwithstanding anything contained in this Agre
Page 18 - Receiving Bank and Nominee: The Company has appointed the Receiving Bank to receive applications and
Page 19 - Several underwriting commitments: Upon and subject to the terms and conditions of this Agreement and
Page 20 - Hong Kong Underwriters set-off: In relation to each Hong Kong Public Offering Application made or pr
Page 21 - Applications and payment for Unsold Hong Kong Offer Shares: In the event of a Hong Kong Public Offer
Page 22 - Reallocation from the International Offering to the Hong Kong Public Offering: If the number of Hong
Page 23 - Hong Kong Underwriters obligations cease: All obligations and liabilities of the Hong Kong Underwrit
Page 24 - Payment to the Company: The application monies received in respect of Hong Kong Public Offering Appl
Page 25 - Brokerage, Trading Fee and Transaction Levy for applicants: The Joint Global Coordinators will, on b
Page 26 - Costs payable by the Company: The Company covenants and agrees with the Hong Kong Underwriters that
Page 27 - 6.3.6, 6.3.8, and 6.3.10 of this section shall not exceed US$30,000 in the aggregate.
Page 28 - Costs remaining payable if the Global Offering does not proceed: If this Agreement shall be terminat
Page 29 - No stabilisation by the Company: The Company undertakes to each of the Joint Sponsors, the Joint Glo
Page 30 - Notice of breach of Warranties: The Company hereby undertakes to forthwith notify the Joint Sponsors
Page 31 - Obligations personal: The obligations of the Company under this Agreement shall be binding on its su
Page 32 - 9.1.1, 9.1.2 or 9.1.3 above,
Page 33 - Full force: The undertakings in this Clause 9 shall remain in full force and effect notwithstanding
Page 34 - Information: provide to the Joint Sponsors, the Joint Global Coordinators and the Hong Kong Underwri
Page 35 - Receiving Bank, Nominee and Hong Kong Registrar: use its best endeavors to procure that each of the
Page 36 - Significant changes: promptly provide full particulars thereof to the Joint Sponsors and the Joint G
Page 37 - Relevant Jurisdiction );
Page 38 - N/A
Page 39 - N/A
Page 40 - Offer-Related Documents ) but excluding information relating to the Underwriters) was, when it was i
Page 41 - Effect of termination: Upon the termination of this Agreement pursuant to the provisions of Clause 1
Page 42 - Losses and individually, a Loss ) which, jointly or severally, any such Indemnified Party may suffer
Page 43 - Indemnified Parties mean the Joint Sponsors, the Joint Global Coordinators and the Hong Kong Underwr
Page 44 - No claims against Indemnified Parties: No Proceeding shall be brought against any Indemnified Party
Page 45 - Arrangements with advisers: If the Indemnifying Party enters into any agreement or arrangement with
Page 46 - Costs: For the avoidance of doubt, the indemnity under this Clause 12 shall cover all costs, charges
Page 47 - ANNOUNCEMENTS
Page 48 - Full force: The restrictions contained in this Clause 14 shall remain in full force and effect notwi
Page 49 - Morgan Stanley, to:
Page 50 - CRS, to:
Page 51 - Waiver of objection to jurisdiction: Each of the parties hereto irrevocably waives (and irrevocably
Page 52 - Exercise of rights: No delay or omission on the part of any party hereto in exercising any right, po
Page 53 - Taxation: All payments to be made by or on behalf of the Company under this Agreement shall be paid
Page 54 - Survival: The provisions in this Clause 17 shall remain in full force and effect notwithstanding the
Page 55 - Schedule 1
Page 56 - N/A
Page 57 - Schedule 2
Page 58 - 2. The Company and the Group
Page 59 - PRC Overseas Investment and Listing Regulations ), including without limitation, requesting each sha
Page 60 - 3. Offer Shares
Page 61 - 5. No conflict, compliance and approvals
Page 62 - FINRA ) of the underwriting terms and arrangements, (B) such consents, approvals, authorizations, or
Page 63 - 6. Accounts and other financial information
Page 64 - Prospective Financial Information ), in each case has been prepared by the Company after due and pro
Page 65 - Critical Accounting Policies ); (B) judgments and uncertainties affecting the application of Critica
Page 66 - 7. Indebtedness and material obligations
Page 67 - 9. Assets
Page 68 - FDA ), the European Medicines Agency ( EMA ), the China Drug Administration ( CDA ) or any comparabl
Page 69 - Applicable Laws ); (B) have not received any FDA Form 483, notice of adverse finding, warning letter
Page 70 - N/A
Page 71 - 10. Compliance with employment and labor Laws
Page 72 - 13. Internal controls
Page 73 - Sarbanes-Oxley Act ) and the rules and regulations promulgated thereunder, the Company has given due
Page 74 - Anti-Money Laundering Laws ); and no action, suit or proceeding by or before any court or government
Page 75 - 16. Provision of information to research analysts
Page 76 - 18. Taxation
Page 77 - 19. Dividends
Page 78 - 22. Choice of law and dispute resolution
Page 79 - 24. United States aspects
Page 80 - 25. Cornerstone Investment
Page 81 - Schedule 3
Page 82 - N/A
Page 83 - N/A
Page 84 - Part B
Page 85 - N/A
Page 86 - Schedule 4
Page 87 - Schedule 5
Page 88 - IN WITNESS whereof this Agreement has been entered into the day and year first before written.
Page 89 - N/A
Page 90 - N/A
Page 91 - N/A
Page 92 - N/A
Page 93 - N/A
Page 94 - N/A
Page 95 - N/A
Page 96 - N/A
Subdocument 3 - EX-99.1 - EX-99.1
Page 1 - Exhibit 99.1
Page 2 - Forward-Looking Statements